Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Analysts at Wedbush lowered their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, down from their prior estimate of ($0.84). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.68) EPS, FY2026 earnings at ($4.23) EPS, FY2027 earnings at ($3.43) EPS and FY2028 earnings at $1.42 EPS.
Several other brokerages also recently issued reports on XENE. Raymond James reissued an “outperform” rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $56.00.
Xenon Pharmaceuticals Stock Up 0.4 %
Shares of NASDAQ XENE opened at $40.11 on Monday. The stock has a market capitalization of $3.06 billion, a P/E ratio of -14.22 and a beta of 1.20. The firm’s 50-day moving average price is $40.20 and its two-hundred day moving average price is $40.82. Xenon Pharmaceuticals has a 52-week low of $35.53 and a 52-week high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the prior year, the company posted ($0.73) EPS.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Loomis Sayles & Co. L P lifted its position in Xenon Pharmaceuticals by 7.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock worth $27,843,000 after buying an additional 46,964 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Xenon Pharmaceuticals by 57.1% during the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock worth $32,480,000 after buying an additional 300,000 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Xenon Pharmaceuticals by 4.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 17,953 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after buying an additional 905,129 shares during the period. Finally, Barclays PLC raised its position in shares of Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after acquiring an additional 13,903 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,383 shares of company stock worth $2,535,891. 5.52% of the stock is currently owned by insiders.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
- Five stocks we like better than Xenon Pharmaceuticals
- Stock Dividend Cuts Happen Are You Ready?
- Sizing Up a New Opportunity for NVIDIA Investors
- Why Invest in 5G? How to Invest in 5G Stocks
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Investing in the High PE Growth Stocks
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.